Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Mikio Kamimura"'
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-4 (2019)
Abstract Background Osteoporosis is a serious disease that causes bone fragility fractures and increases mortality. Bisphosphonates are the first-line drugs for osteoporosis. However, the gains in bone mineral density by use of bisphosphonates alone
Externí odkaz:
https://doaj.org/article/afca0f3257834deb86d611f691efe0a0
Autor:
Mikio Kamimura, Shota Ikegami, Keijiro Mukaiyama, Hidefumi Koiwai, Yukio Nakamura, Akira Taguchi, Hiroyuki Kato
Publikováno v:
Osteoporosis and Sarcopenia, Vol 5, Iss 2, Pp 57-61 (2019)
Objectives: We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a poor respon
Externí odkaz:
https://doaj.org/article/bed27f74925c425b89d1ccd3782d5623
Publikováno v:
Bone Reports, Vol 8, Iss , Pp 110-114 (2018)
The purpose of our study was to compare the skeletal responses to 3-year denosumab treatment in bisphosphonate (BP)-naïve and long-term BP-treated patients with postmenopausal osteoporosis. Female patients who were BP treatment-naïve (treatment-na
Externí odkaz:
https://doaj.org/article/82703acdf8af430e82a60b6506293bbd
Autor:
Takako Suzuki, Yukio Nakamura, Mikio Kamimura, Shota Ikegami, Shigeharu Uchiyama, Hiroyuki Kato
Publikováno v:
Osteoporosis and Sarcopenia, Vol 3, Iss 2, Pp 108-111 (2017)
Objectives: The aim of this study was to examine the discontinuation and occurrence of fracture during denosumab treatment in Japanese women with primary osteoporosis or rheumatoid arthritis (RA) with osteoporosis. Methods: This retrospective study i
Externí odkaz:
https://doaj.org/article/98d595012e3143f9b0514e33169b945d
Autor:
Shota Ikegami, Mikio Kamimura, Hiroyuki Nakagawa, Kenji Takahara, Hiroyuki Hashidate, Shigeharu Uchiyama, Hiroyuki Kato
Publikováno v:
Orthopedic Reviews, Vol 1, Iss 2, Pp e21-e21 (2009)
Healing of fractures is different for each bone and bone turnover markers may reflect the fracture healing process. The purpose of this study was to determine the characteristic changes in bone turnover markers during the fracture healing process. Th
Externí odkaz:
https://doaj.org/article/1c5f100595294e9aa36c09e0ea96b056
Publikováno v:
Modern Rheumatology Case Reports. 5:178-181
Osteoporosis (OP) is a common disease in the elderly that causes bone fractures and increases mortality. Denosumab (DMAB) is one of several medications to treat OP. DMAB not only reduces the risk of fractures, but also improves the quality of life. H
Autor:
Masatoshi Komatsu, Akira Ichinose, Kenji Takahara, Hiroyuki Kato, Mikio Kamimura, Ryohei Ashizawa, Akira Taguchi, Hidefumi Koiwai, Shigeharu Uchiyama
Publikováno v:
Osteoporosis International. 30:621-628
In osteoporosis patients receiving antiresorptive medications, stopping the drug and delaying tooth extraction has been suggested to reduce the risk of osteonecrosis of the jaw (ONJ). However, postponing tooth extraction for ≥ 2 months was associat
Publikováno v:
Modern rheumatology case reports. 4(2)
In recent years, several studies have shown that multiple vertebral fractures sometimes occur after denosumab discontinuation. Herein, we report the case of a 63-year-old woman with osteoporosis who lost 60% of lumbar bone mineral density acquired du
Background: Ankle sprains are one of the most common musculoskeletal injuries. However, they may be more serious than commonly believed since many patients reportedly experience chronic problems afterwards. It is necessary to improve the treatment, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6dfa356db39fa1c9078e683b6b852bc
https://doi.org/10.21203/rs.3.rs-68756/v1
https://doi.org/10.21203/rs.3.rs-68756/v1
Autor:
Takako Suzuki, Shigeharu Uchiyama, Yukio Nakamura, Hiroyuki Kato, Tomoki Kosho, Masashi Uehara, Tomomi Yamaguchi, Mikio Kamimura, Jun Takahashi, Fumihiro Isobe
Publikováno v:
Therapeutics and Clinical Risk Management. 14:1243-1246
Background The natural history and pathogenesis of the skeletal abnormalities found in neurofibromatosis type 1 (NF1) are poorly understood, and the therapeutic options for these manifestations remain limited. This report first describes the clinical